Search ARM

Oncology & Regenerative Medicine

This report provides industry specific statistics compiled from gene therapy, gene-modified cell therapy, cell therapy, and other regenerative medicine companies active in developing therapies to treat cancer and provides context for the potential of regenerative medicine to improve upon the current standard of care.

As of June 2019:

There are 416+ companies worldwide working on regenerative medicine therapies in oncology, including 191 clinical-stage companies.

There are currently 132+ products in active development with 627 clinical trials ongoing, including 23 in Phase III.

Cancer causes one in six deaths worldwide, 18+ million people diagnosed with cancer each year and more than 9 million deaths attributed to cancer annually.


View Full Report


Clinical trials underway
worldwide as of June 2019

PH. 1


PH. 2


PH. 3


Clinical Trials by Technology Type

Gene Therapy
Gene-Modified Cell Therapy
Oncolytic Virus
Cell Therapy

Clinical Trials by Indication

Companies Active in Developing Regenerative Medicines in Oncology



Global Financings for Regenerative Medicines in Oncology